

Cp^{*}Co^{III}-catalyzed formal [4 + 2] cycloaddition of benzamides to afford quinazolinone derivatives

Jingshu Yang,^{‡a} Xiao Hu,^{‡a} Zijie Liu,^{b,c} Xueyuan Li,^a Yi Dong,^{*b,c} and Gang Liu^{*a}

^a School of Pharmaceutical Sciences, Tsinghua University, Haidian District, Beijing 100084,, China. E-mail: gangliu27@tsinghua.edu.cn.

^b. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. E-mail: dongyi@imm.ac.cn.

^c. Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

[‡] These authors contributed equally.

Table of cotent

| | |
|-------------------------------------------------------------------------------------------------------------------------------------|------------|
| <i>General methods.....</i> | <i>S1</i> |
| <i>H/D exchange experiment.....</i> | <i>S2</i> |
| <i>KIE experiment.....</i> | <i>S4</i> |
| <i>Preparation of amides and dioxazolones.....</i> | <i>S5</i> |
| <i>General procedure for Co(III)-catalyzed C(sp²)-H amidation of benzamides to afford quinazolinone derivatives.....</i> | <i>S12</i> |
| <i>Reference.....</i> | <i>S23</i> |
| <i>Copies of NMR spectra of products.....</i> | <i>S24</i> |

General methods


Dried solvent, such as DCM, DCE, MeOH and THF were purchased from domestic corporations and used without purification. $[\text{Cp}^*\text{Co}(\text{CO})\text{I}_2]$ was purchased from domestic corporation, AgSbF₆, AgNtf₂, AgOAc, AgBF₄ and AgOTf were purchased from Alfa. Analytical thin layer chromatography (TLC) plates, preparative TLC and the silica gel for column chromatography were phased from Qingdao Haiyang Chemical and Special Silica Gel Co, Ltd.


High-resolution LC-MS was carried out by Agilent LC/MSD TOF using a column of Agilent ZORBAX SB-C18 (rapid resolution, 3.5 μm , 2.1 \times 30 mm) at a flow of 0.40 mL/min. The solvent was MeOH/water (75:25 (v/v)), containing 5 mmol/L ammonium formate. The ion source is electrospray ionization (ESI).

Proton nuclear magnetic resonance (¹H NMR) and carbon nuclear magnetic resonance (¹³C NMR) spectroscopy were performed on Bruker Advance 400M NMR spectrometers or 500M NMR spectrometers. Chemical shifts of ¹H NMR spectra are reported as in units of parts per million (ppm) downfield from SiMe₄ (δ 0.0) and relative to the signal of chloroform-*d* (δ = 7.260, singlet) and DMSO-*d*6 (δ = 2.500, quintet). Multiplicities were given as: s (singlet); d (doublet); t (triplet); q (quartet); dd (doublet of doublets); m (multiplets), etc. The number of protons (n) for a given resonance is indicated by nH. Carbon nuclear magnetic resonance spectra (¹³C NMR) are reported as in units of parts per million (ppm) downfield from SiMe₄ (δ 0.0) and relative to the signal of chloroform-*d* (δ = 77.230, triplet) and DMSO-*d*6 (δ = 39.510, septet).

H/D exchange experiment


A mixture of $[\text{Cp}^*\text{Co}(\text{CO})\text{I}_2]$ (5.0 mol%), AgNTf_2 (10 mol%), $\text{Zn}(\text{OAc})_2$ (1 eq) and benzamide **1s** (0.2 mmol) in 2.0 mL DCE and 0.5 mL [D4]-MeOH was heated to 120°C, and stirred overnight. Then the reaction mixture was cooled to room temperature and filtered, the filtrate was concentrated and the residue was purified with flash column chromatography. 10% deuteration on phenyl C-H was detected.






KIE experiment

The parallel reactions with **1m** and deuterated substrate **1m-d₅** under the standard conditions were proceeded: A mixture of [Cp*Co(CO)I₂] (5.0 mol%), AgNTf₂ (10 mol%), Zn(OAc)₂ (1 eq) and benzamide **1m** or **1m-d₅** (0.2 mmol) and 3-methyl-1,4,2-dioxazol-5-one (0.24 mmol) in 2.0 mL DCE was heated to 120°C 1h. Then the two reaction mixtures were combined, cooled to room temperature and filtered, the filtrate was concentrated and the residue was purified with flash column chromatography. KIE value ($k_H/K_D = 1.2$) was determined by ¹H NMR analysis.




General procedure for synthesis of amides and dioxazolones:

A. General procedure for synthesis of amides



B. General procedure for synthesis of dioxazolones



Method A: Acyl chloride (10 mmol) and trimethylamine (1.67 mL, 12 mmol) were dissolved in 20 mL DCM at 0 °C, then amine (12 mmol) was added. The reaction was allowed to warm to room temperature and stirred overnight. The reaction was quenched by water. DCM was used to extract the product from the aqueous layer. The combined organic layer was washed with water (3×50 mL), dried over Na₂SO₄, filtered and concentrated. The crude product was purified by silica gel chromatography.


Method B: To a suspension of 1,1-Carbonyldimidazole (2.43 g, 15 mmol) in THF (30 mL) was added carboxylic acid (10 mmol) and hydroxylamine hydrochloride (1.67 g, 20 mmol), and stirred at room temperature overnight. When the starting material was consumed completely, the reaction mixture was filtered and washed with THF. The filtrate was concentrated and purified by silica gel chromatography.

Method C¹: To a solution of hydroxamic acid (10 mmol) in DCM (100 mL) was added 1,1-Carbonyldimidazole (1.62 g, 10 mmol). The resulting solution was stirred at room temperature and for 0.5h. Then the mixture was quenched with 1 M HCl, extracted with dichloromethane, washed by water and dried over anhydrous Na₂SO₄. The solvent was evaporated under the reduced pressure to afford the crude product.

Method D: Hydroxylamine hydrochloride (2.48 g, 36 mmol) was added to a biphasic mixture of


K_2CO_3 (8.28 g, 60 mmol) in a 2:1 mixture of EtOAc (120 mL) and H_2O (60 mL). The resulting solution was cooled to 0 °C followed by dropwise addition of acyl chloride (30 mmol) dissolved in a minimum amount of EtOAc. The reaction was allowed to warm to room temperature and stirred for 2 h. EtOAc was used to extract the product from the aqueous layer. The combined organic layer was washed with water (3×50 mL), dried over Na_2SO_4 , filtered and concentrated to afford the crude product.

3-methyl-N-(methylsulfonyl) benzamide (1ab)




Method A. White solid (2.0 g, 94%), $R_f = 0.4$ (EtOAc/Petroleum ether = 1:1). ^1H NMR (400 MHz, DMSO-*d*6) δ 12.06 (br s, 1H), 7.77 (s, 1H), 7.75 – 7.67 (m, 1H), 7.59 – 7.22 (m, 2H), 3.36 (s, 3H), 2.37 (s, 3H). ^{13}C NMR (101 MHz, DMSO-*d*6) δ 166.5, 138.0, 133.8, 131.7, 128.9, 128.5, 125.6, 41.3, 20.8. MS (m/z) [M + H]⁺: 214.25.

N-(tert-butyl)-3-methylbenzamide (1ac)




Method A. White solid (1.2 g, 63%), $R_f = 0.4$ (EtOAc/Petroleum ether = 1:1). ^1H NMR (400 MHz, DMSO-*d*6) δ 7.68 (s, 1H), 7.60 (s, 1H), 7.59 – 7.52 (m, 1H), 7.30 (dd, $J = 8.8, 4.3$ Hz, 2H), 2.34 (s, 3H), 1.37 (s, 9H). ^{13}C NMR (101 MHz, DMSO-*d*6) δ 166.4, 137.2, 135.9, 131.2, 127.9, 127.8, 124.5, 50.7, 28.6, 20.9. MS (m/z) [M + H]⁺: 192.27.

N-methoxy-3-methylbenzamide (1a)




Method B. White solid (1.6 g, 97%), $R_f = 0.2$ (EtOAc/Petroleum ether = 1:1). ^1H NMR (400 MHz, CDCl_3) δ 8.92 (br s, 1H), 7.57 (s, 1H), 7.51 (d, $J = 6.6$ Hz, 1H), 7.38 – 7.28 (m, 2H), 3.89 (s, 3H), 2.39 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 166.9, 138.8, 133.0, 131.8, 128.7, 127.8, 124.0, 64.7, 21.5. MS (m/z) [M + H]⁺: 166.19.

N,3-dimethylbenzamide (1b)



Method A. White solid (1.3 g, 87%), $R_f = 0.3$ (EtOAc/Petroleum ether = 1:1). ^1H NMR (400 MHz, DMSO-*d*6) δ 8.37 (s, 1H), 7.64 (s, 1H), 7.63 – 7.57 (m, 1H), 7.40 – 7.20 (m, 2H), 2.77 (d, $J = 4.6$ Hz, 3H), 2.35 (s, 3H). ^{13}C NMR (101 MHz, DMSO-*d*6) δ 166.7, 137.5, 134.5, 131.5, 128.1, 127.6, 124.1, 26.2, 21.0. MS (m/z) [M + H]⁺: 150.19.

N-butyl-3-methylbenzamide (1c)




Method B. Colourless soil (1.8 g, 94%), $R_f = 0.3$ (EtOAc/Petroleum ether = 1:1). ^1H NMR (400 MHz, CDCl_3) δ 7.58 (s, 1H), 7.52 (dd, $J = 4.8, 3.6$ Hz, 1H), 7.29 (dd, $J = 4.0, 1.7$ Hz, 2H), 6.17 (br s, 1H), 3.44 (dd, $J = 12.9, 7.1$ Hz, 2H), 2.38 (s, 3H), 1.66 – 1.54 (m, 2H), 1.41 (dq, $J = 14.5, 7.3$ Hz, 2H), 0.95 (t, $J = 7.3$ Hz, 3H). ^{13}C

NMR (101 MHz, CDCl₃) δ 167.9, 138.5, 135.0, 132.1, 128.5, 127.8, 123.9, 39.9, 31.9, 21.5, 20.3, 13.9.


MS (m/z) [M + H]⁺: 192.15.

N-benzyl-3-methylbenzamide (1d)




Method B. White solid (2.1 g, 93%), R_f = 0.2 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl₃) δ 7.62 (s, 1H), 7.57 (dd, J = 6.0, 2.6 Hz, 1H), 7.35 (d, J = 4.3 Hz, 4H), 7.33 – 7.27 (m, 3H), 6.53 (br s, 1H), 4.72 – 4.58 (m, 2H), 2.38 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 167.7, 138.6, 138.4, 134.5, 132.4, 128.9, 128.6, 128.0, 127.9, 127.7, 124.0, 44.2, 21.5. **MS** (m/z) [M + H]⁺: 226.12.

N,3-dimethoxybenzamide (1e)




Method B. Colourless oil (1.0 g, 55%), R_f = 0.3 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl₃) δ 8.75 (br s, 1H), 7.39 – 7.28 (m, 2H), 7.24 (d, J = 7.6 Hz, 1H), 7.06 (dd, J = 8.2, 2.4 Hz, 1H), 3.89 (s, 3H), 3.84 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 166.6, 160.0, 133.3, 129.9, 118.9, 118.6, 112.4, 64.8, 55.6. **MS** (m/z) [M + H]⁺: 182.19.

3-(dimethylamino)-N-methoxybenzamide (1f)




Method B. White solid (1.3 g, 67%), R_f = 0.4 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl₃) δ 9.01 (s, 1H), 7.25 – 7.20 (m, 1H), 7.14 (s, 1H), 6.96 (d, J = 7.5 Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H), 3.86 (d, J = 1.4 Hz, 3H), 2.98 (s, 3H), 2.97 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 167.3, 150.6, 132.8, 129.4, 116.0, 114.4, 111.3, 64.9, 64.7, 40.7. **MS** (m/z) [M + H]⁺: 195.23.

N-methoxy-[1,1'-biphenyl]-3-carboxamide (1g)



Method B. White solid (1.6 g, 70%), R_f = 0.2 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl₃) δ 9.32 (br s, 1H), 7.97 (s, 1H), 7.74 – 7.67 (m, 2H), 7.57 (d, J = 7.2 Hz, 2H), 7.51 – 7.39 (m, 3H), 7.38 – 7.33 (m, 1H), 3.87 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 166.7, 142.0, 140.1, 132.4, 130.8, 129.3, 129.0, 128.0, 127.3, 126.0, 125.8, 64.6. **MS** (m/z) [M + H]⁺: 228.26.


3-chloro-N-methoxybenzamide (1h)



Method B. White solid (1.2 g, 65%), R_f = 0.3 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl₃) δ 8.91 (br s, 1H), 7.73 (s, 1H), 7.61 (d, J = 7.7 Hz, 1H), 7.50 (d, J = 8.1 Hz, 1H), 7.42 – 7.34 (m, 1H), 3.88 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 167.7, 138.6, 138.4, 134.5, 132.4, 128.9, 128.6, 128.0, 127.9, 127.7, 124.0, 44.2, 21.5. **MS** (m/z) [M + H]⁺: 226.12.


MHz, CDCl₃) δ 165.4, 135.1, 133.7, 132.3, 130.2, 127.5, 125.3, 64.8. **MS** (m/z) [M + H]⁺: 186.01.

3-bromo-N-methoxybenzamide (1i)




Method B. White solid (1.9 g, 83%), R_f = 0.3 (EtOAc/Petroleum ether = 1:1). **1H NMR** (400 MHz, CDCl₃) δ 9.95 (s, 1H), 7.91 (d, J = 1.5 Hz, 1H), 7.69 (d, J = 7.8 Hz, 1H), 7.60 (dd, J = 8.0, 0.7 Hz, 1H), 7.28 – 7.23 (m, 1H), 3.83 (s, 3H). **13C NMR** (101 MHz, CDCl₃) δ 165.1, 135.1, 133.7, 130.4, 130.3, 125.8, 122.8, 64.5. **MS** (m/z) [M + H]⁺: 229.97.

Methyl 3-(methoxycarbamoyl) benzoate (1j)




Method B. White solid (1.3 g, 62%), R_f = 0.5 (EtOAc/Petroleum ether = 1:1). **1H NMR** (400 MHz, DMSO-d6) δ 11.98 (s, 1H), 8.34 (s, 1H), 8.10 (s, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.74 – 7.41 (m, 1H), 3.98 – 3.84 (m, 3H), 3.73 (s, 3H). **13C NMR** (101 MHz, DMSO-d6) δ 165.7, 163.1, 132.8, 132.1, 131.7, 129.9, 129.2, 127.8, 63.3, 52.4. **MS** (m/z) [M + H]⁺: 210.11.

3-acetyl-N-methoxybenzamide (1k)




Method B. White solid (0.9 g, 47%), R_f = 0.3 (EtOAc/Petroleum ether = 3:1). **1H NMR** (400 MHz, CDCl₃) δ 9.93 (s, 1H), 8.35 (s, 1H), 8.06 (d, J = 7.7 Hz, 1H), 8.02 (d, J = 7.7 Hz, 1H), 7.55 – 7.50 (m, 1H), 3.88 (s, 3H), 2.62 (s, 3H). **13C NMR** (101 MHz, CDCl₃) δ 197.9, 160.4, 137.3, 132.4, 132.1, 131.7, 129.2, 126.8, 64.8, 26.8. **MS** (m/z) [M + H]⁺: 194.21.

N-methoxy-3-nitrobenzamide (1l)




Method B. White solid (1.2 g, 61%), R_f = 0.4 (EtOAc/Petroleum ether = 1:1). **1H NMR** (400 MHz, DMSO-d6) δ 12.14 (s, 1H), 8.56 (s, 1H), 8.40 (d, J = 8.0 Hz, 1H), 8.19 (d, J = 7.8 Hz, 1H), 7.81 – 7.77 (m, 1H), 3.75 (s, 3H). **13C NMR** (101 MHz, DMSO-d6) δ 161.8, 147.8, 133.6, 133.5, 130.4, 126.3, 121.8, 63.5. **MS** (m/z) [M + H]⁺: 197.05.

N-methoxybenzamide (1m)




Method B. White solid (1.5 g, 99%), R_f = 0.2 (EtOAc/Petroleum ether = 1:1). **1H NMR** (400 MHz, DMSO-d6) δ 11.72 (br s, 1H), 7.75 (d, J = 7.7 Hz, 2H), 7.58 – 7.52 (m, 1H), 7.50 – 7.44 (m, 2H), 3.71 (s, 3H). **13C NMR** (101 MHz, DMSO-d6) δ 164.1, 132.3, 131.6, 128.4, 127.0, 63.2. **MS** (m/z) [M + H]⁺: 152.17.

N-methoxy-[1,1'-biphenyl]-4-carboxamide (**1n**)




Method B. White solid (2.0 g, 88%), R_f = 0.2 (EtOAc/Petroleum ether = 1:1). ^1H NMR (400 MHz, DMSO-*d*6) δ 11.81 (s, 1H), 7.85 (d, J = 8.1 Hz, 2H), 7.81 – 7.75 (m, 2H), 7.72 (d, J = 7.6 Hz, 2H), 7.52 – 7.46 (m, 2H), 7.43 – 7.36 (m, 1H), 3.73 (s, 3H). ^{13}C NMR (101 MHz, DMSO-*d*6) δ 163.8, 159.3, 143.1, 139.0, 131.0, 129.0, 128.1, 127.7, 126.9, 126.7, 63.3. MS (m/z) [M + H]⁺: 228.26.

N-methoxy-4-methylbenzamide (**1o**)




Method B. White solid (1.6 g, 97%), R_f = 0.3 (EtOAc/Petroleum ether = 1:1). ^1H NMR (400 MHz, CDCl₃) δ 8.98 (br s, 1H), 7.64 (d, J = 7.9 Hz, 2H), 7.20 (d, J = 6.2 Hz, 2H), 3.85 (d, J = 3.4 Hz, 3H), 2.38 (s, 3H). ^{13}C NMR (101 MHz, CDCl₃) δ 166.7, 142.6, 129.4, 129.1, 127.2, 64.5, 21.6. MS (m/z) [M + H]⁺: 166.21.

4-chloro-*N*-methoxybenzamide (**1p**)




Method B. White solid (1.1 g, 59%), R_f = 0.2 (EtOAc/Petroleum ether = 1:1). ^1H NMR (400 MHz, CDCl₃) δ 8.7 (br s, 1H), 7.7 (d, J = 8.5 Hz, 2H), 7.4 (d, J = 8.5 Hz, 2H), 3.89 (s, 3H). ^{13}C NMR (101 MHz, CDCl₃) δ 165.1, 138.5, 130.0, 129.1, 128.6, 64.6. MS (m/z) [M + H]⁺: 186.22.

N-methoxy-4-nitrobenzamide (**1q**)




Method B. White solid (1.5 g, 77%), R_f = 0.4 (EtOAc/Petroleum ether = 1:1). ^1H NMR (400 MHz, DMSO-*d*6) δ 12.11 (br s, 1H), 8.32 (d, J = 8.6 Hz, 2H), 7.98 (d, J = 8.6 Hz, 2H), 3.73 (s, 3H). ^{13}C NMR (101 MHz, DMSO-*d*6) δ 162.3, 149.3, 138.0, 128.6, 123.7, 63.4. MS (m/z) [M + H]⁺: 197.16.

N-methoxy-4-(trifluoromethyl) benzamide (**1r**)



Method B. White solid (2.0 g, 91%), R_f = 0.3 (EtOAc/Petroleum ether = 1:1). ^1H NMR (400 MHz, DMSO-*d*6) δ 11.99 (s, 1H), 7.95 (d, J = 8.1 Hz, 2H), 7.84 (d, J = 7.9 Hz, 2H), 3.73 (s, 3H). ^{13}C NMR (101 MHz, DMSO-*d*6) δ 162.8, 136.1, 131.5 (q, J = 32.4 Hz), 128.0, 125.5 (d, J = 3.5 Hz), 123.8 (d, J = 272.5 Hz), 63.3. MS (m/z) [M + H]⁺: 220.03.


N-methoxy-2-methylbenzamide (**1s**)



Method B. White solid (1.2 g, 73%), R_f = 0.3 (EtOAc/Petroleum ether = 1:1). ^1H NMR (400 MHz, CDCl₃) δ 8.28 (br s, 1H), 7.35 – 7.28 (m, 2H), 7.24 – 7.13 (m,


2H), 3.85 (s, 3H), 2.42 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 160.2, 137.0, 132.7, 131.2, 130.7, 127.2, 125.8, 64.7, 19.6. **MS** (m/z) [M + H]⁺: 166.19.

2-bromo-N-methoxybenzamide (1t)




Method B. White solid (2.0 g, 88%), R_f = 0.3 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl₃) δ 8.67 (br s, 1H), 7.58 (d, J = 7.9 Hz, 1H), 7.48 (d, J = 7.1 Hz, 1H), 7.35 (dd, J = 10.7, 4.1 Hz, 1H), 7.32 – 7.27 (m, 1H), 3.91 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 165.4, 160.2, 133.5, 132.0, 130.0, 127.7, 120.0, 64.9. **MS** (m/z) [M + H]⁺: 229.97.

N-methoxy-2,4-dimethylbenzamide (1u)




Method B. White solid (1.3 g, 73%), R_f = 0.3 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz) δ 11.38 (s, 1H), 7.22 (dd, J = 15.2, 7.3 Hz, 1H), 7.06 (dd, J = 22.8, 11.1 Hz, 2H), 3.71 (s, 3H), 2.34 (d, J = 10.4 Hz, 2H), 2.30 (d, J = 10.0 Hz, 4H). **¹³C NMR** (101 MHz) δ 166.0, 139.5, 135.9, 131.2, 131.1, 127.4, 126.0, 63.2, 20.8, 19.1. **MS** (m/z) [M + H]⁺: 180.21.

4-bromo-3-chloro-N-methoxybenzamide (1v)




Method B. White solid (2.1 g, 80%), R_f = 0.2 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl₃) δ 9.6 (s, 1H), 7.9 (d, J = 1.9 Hz, 1H), 7.7 (d, J = 8.3 Hz, 1H), 7.5 (dd, J = 8.3, 1.9 Hz, 1H), 3.9 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 168.0, 135.3, 134.2, 132.1, 129.1, 126.9, 126.4, 64.5. **MS** (m/z) [M + H]⁺: 263.93.

N-methoxy-1-naphthamide (1w)



Method B. White solid (1.5 g, 75%), R_f = 0.4 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, DMSO-d6) δ 11.73 (s, 1H), 8.19 (d, J = 7.8 Hz, 1H), 8.06 (d, J = 8.1 Hz, 1H), 7.99 (dd, J = 8.0, 6.5 Hz, 1H), 7.64 – 7.58 (m, 3H), 7.57 – 7.52 (m, 1H), 3.82 (s, 3H). **¹³C NMR** (101 MHz, DMSO-d6) δ 165.5, 133.2, 131.5, 130.5, 129.9, 128.4, 127.1, 126.5, 125.8, 125.0(X2), 63.4. **MS** (m/z) [M + H]⁺: 202.21.


2-(tert-butyl)-N-methoxybenzo[d]oxazole-7-carboxamide (1x)



Method B. Yellow oil (2.0 g, 81%), R_f = 0.4 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (500 MHz, CDCl₃) δ 8.08 (d, J = 7.3 Hz, 1H), 7.85 (d, J = 7.5 Hz, 1H), 7.45 – 7.42 (m, 1H), 7.32 (s, 1H), 3.98 (s, 3H), 1.55 (s, 9H). **¹³C NMR** (101 MHz, CDCl₃) δ


173.3, 162.0, 147.3, 141.5, 126.1, 124.7, 124.0, 114.6, 65.0, 34.4, 28.6. **MS** (m/z) [M + H]⁺: 249.13 .

N-methoxybenzamide-2,3,4,5,6-d₅ (1m-d₅)




To a suspension of toluene-d₈ (0.5g, 5 mmol) in H₂O (20 mL) was added MgSO₄ (1.2 g, 10 mmol) and KMnO₄ (3.16 g, 20 mmol), and refluxed overnight. When the starting material was consumed completely, the reaction mixture was filtered and washed with EtOAc. The filtrate was concentrated and purified by silica gel chromatography to benzoic acid-d₅. The title compound was given from benzoic acid-d₅ according to method B. Yellow oil (1.2 g, 77%), R_f = 0.2 (EtOAc/Petroleum ether = 1:1). **1H NMR** (400 MHz, DMSO-d6) δ 11.74 (s, 1H), 3.71 (s, 3H). **MS** (m/z) [M + H]⁺: 157.12.

3-methyl-1,4,2-dioxazol-5-one (2a)




Method C. Colourless oil (0.7 g, 69%). **1H NMR** (400 MHz, CDCl₃) δ 2.35 (s, 3H). **13C NMR** (101 MHz, CDCl₃) δ 163.9, 154.2, 10.6.

3-heptyl-1,4,2-dioxazol-5-one (2b)




Method C. Colourless oil (1.3 g, 70%). **1H NMR** (400 MHz, CDCl₃) δ 2.62 (t, J = 7.5 Hz, 2H), 1.75 – 1.68 (m, 2H), 1.36 – 1.26 (m, 8H), 0.90 – 0.87 (m, 3H). **13C NMR** (101 MHz, CDCl₃) δ 166.9, 154.4, 31.6, 28.8, 28.7, 24.9, 24.7, 22.7, 14.2.

3-isopentyl-1,4,2-dioxazol-5-one (2c)



Method C and D. Colourless oil (1.3 g, 83%). **1H NMR** (400 MHz, CDCl₃) δ 2.67 – 2.58 (m, 2H), 1.69 – 1.63 (m, 1H), 1.59 (dt, J = 7.3, 2.7 Hz, 2H), 0.94 (d, J = 6.3 Hz, 6H). **13C NMR** (101 MHz, CDCl₃) δ 167.1, 154.4, 33.2, 27.5, 22.9, 22.1.

3-(3-(benzyloxy)propyl)-1,4,2-dioxazol-5-one (2d)




Method C and D. Yellow oil (2.0 g, 85%). **1H NMR** (400 MHz, CDCl₃) δ 7.37 – 7.33 (m, 2H), 7.33 – 7.28 (m, 3H), 4.50 (s, 2H), 3.56 (t, J = 5.7 Hz, 2H), 2.76 (t, J = 7.3 Hz, 2H), 2.06 – 1.90 (m, 2H). **13C NMR** (101 MHz, CDCl₃) δ 166.7, 154.3, 138.0, 128.6, 128.0, 127.8, 73.3, 68.1, 24.9, 22.2.


General procedure for Co(III)-catalyzed C(sp²)–H amidation of benzamides to afford quinazolinone derivatives:

A mixture of [Cp*Co(CO)I₂] (5.0 mol%), AgNTf₂ (10 mol%), Zn(OAc)₂ (1 eq) and benzamide (0.2 mmol), and dioxazolone (0.24 mmol) in 2.0 mL DCE was heated to 120°C, and stirred overnight. Then the reaction mixture was cooled to room temperature and filtered, the filtrate was concentrated and the residue was purified with silica gel to afford quinazolinone derivatives.


2-acetamido-5-methylbenzamide (3aa')




2-acetamido-N-(tert-butyl)-5-methylbenzamide (3ca')




2,3,6-trimethylquinazolin-4(3H)-one (3da)



3-methoxy-2,6-dimethylquinazolin-4(3H)-one (3ea)




3-butyl-2,6-dimethylquinazolin-4(3*H*)-one (4)




Colourless oil (28 mg, 60%), R_f = 0.2 (EtOAc/Petroleum ether = 1:1). **^1H NMR** (400 MHz, CDCl_3) δ 8.02 (s, 1H), 7.61 – 7.40 (m, 2H), 4.28 – 3.88 (m, 2H), 2.64 (s, 3H), 2.46 (s, 3H), 1.70 (ddd, J = 12.5, 8.7, 6.6 Hz, 2H), 1.52 – 1.39 (m, 2H), 0.99 (t, J = 7.3 Hz, 3H). **^{13}C NMR** (101 MHz, CDCl_3) δ 162.1, 153.5, 145.1, 136.7, 135.8, 126.3 (X2), 120.3, 44.6, 30.9, 23.1, 21.4, 20.4, 13.9. **HRMS** (ESI): m/z (M + H $^+$) calcd for $\text{C}_{14}\text{H}_{19}\text{O}_1\text{N}_2$, 231.1499, found: 231.1492.

3-benzyl-2,6-dimethylquinazolin-4(3*H*)-one (5)




White solid (35 mg, 67%), R_f = 0.2 (EtOAc/Petroleum ether = 1:1). **^1H NMR** (400 MHz, CDCl_3) δ 8.10 (s, 1H), 7.61 – 7.52 (m, 2H), 7.35 – 7.25 (m, 3H), 7.22 – 7.17 (m, 2H), 5.40 (s, 2H), 2.54 (s, 3H), 2.49 (s, 3H). **^{13}C NMR** (101 MHz, CDCl_3) δ 162.5, 153.9, 145.3, 136.9, 136.1 (X2), 129.1, 127.8, 126.7 (X2), 126.6, 120.2, 47.3, 23.5, 21.4. **HRMS** (ESI): m/z (M + H $^+$) calcd for $\text{C}_{17}\text{H}_{17}\text{O}_1\text{N}_2$, 265.1342 found: 265.1335. **mp** 100–101 °C.

3,6-dimethoxy-2-methylquinazolin-4(3*H*)-one (6)




White solid (34 mg, 78%), R_f = 0.6 (EtOAc/Petroleum ether = 1:1). **^1H NMR** (400 MHz, CDCl_3) δ 7.83 (d, J = 2.7 Hz, 1H), 7.80 (d, J = 8.9 Hz, 1H), 7.56 (dd, J = 9.0, 2.7 Hz, 1H), 4.35 (s, 3H), 4.15 (s, 3H), 2.85 (s, 3H). **^{13}C NMR** (101 MHz, CDCl_3) δ 158.2, 157.7, 151.0, 141.1, 128.6, 124.8, 123.4, 106.0, 64.1, 55.9, 19.8. **HRMS** (ESI): m/z (M + H $^+$) calcd for $\text{C}_{11}\text{H}_{13}\text{N}_2\text{O}_3$, 221.0926, found: 221.0921. **mp** 147–149 °C.

6-(dimethylamino)-3-methoxy-2-methylquinazolin-4(3*H*)-one (7)



Yellow solid (35 mg, 75%), R_f = 0.4 (EtOAc/Petroleum ether = 1:1). **^1H NMR** (400 MHz, CDCl_3) δ 7.51 (d, J = 9.0 Hz, 1H), 7.33 (d, J = 3.0 Hz, 1H), 7.19 (dd, J = 9.0, 3.0 Hz, 1H), 4.09 (s, 3H), 3.04 (s, 6H), 2.58 (s, 3H). **^{13}C NMR** (101 MHz, CDCl_3) δ 158.1, 149.0, 149.0, 137.6, 127.9, 123.5, 120.5, 105.7, 64.1, 40.7 (X2), 19.8. **HRMS** (ESI): m/z (M + H $^+$) calcd for $\text{C}_{12}\text{H}_{16}\text{N}_3\text{O}_2$, 234.1237, found: 234.1235. **mp** 115–116 °C.


3-methoxy-2-methyl-6-phenylquinazolin-4(3*H*)-one (8)




Yellow solid (50 mg, 94%), R_f = 0.6 (EtOAc/Petroleum ether = 1:1). **^1H NMR** (400 MHz, CDCl_3) δ 8.45 (s, 1H), 7.95 (dd, J = 8.1, 1.5 Hz, 1H), 7.69 – 7.64 (m, 3H), 7.47 – 7.42 (m, 2H), 7.38 – 7.34 (m, 1H), 4.11 (s, 3H), 2.63 (s, 3H). **^{13}C NMR** (101 MHz, CDCl_3) δ 157.9, 153.3, 145.6, 139.4 (X2), 133.3, 129.1, 128.0, 127.6, 127.2, 124.5,

122.9, 64.2, 20.1. **HRMS** (ESI): m/z (M + H⁺) calcd for C₁₆H₁₅N₂O₂, 267.1128, found: 267.1126. **mp** 129–130 °C.


6-chloro-3-methoxy-2-methylquinazolin-4(3*H*)-one (9)




6-bromo-3-methoxy-2-methylquinazolin-4(3*H*)-one (10)




Methyl 3-methoxy-2-methyl-4-oxo-3,4-dihydroquinazoline-6-carboxylate (11)



6-acetyl-3-methoxy-2-methylquinazolin-4(3*H*)-one (12)




3-methoxy-2-methyl-6-nitroquinazolin-4(3*H*)-one (13)




CDCl_3) δ 157.2, 156.7, 150.4, 145.4, 128.9, 128.5, 123.4, 122.8, 64.5, 20.4. **HRMS** (ESI): m/z (M + H⁺) calcd for $\text{C}_{10}\text{H}_{10}\text{N}_3\text{O}_4$, 236.0666, found: 236.0664. **mp** 150–152 °C.

3-methoxy-2-methylquinazolin-4(3*H*)-one (14)




White solid (31 mg, 81%), R_f = 0.5 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl_3) δ 8.21 (dd, J = 8.0, 1.1 Hz, 1H), 7.72 – 7.66 (m, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.40 (dd, J = 11.2, 3.9 Hz, 1H), 4.08 (s, 3H), 2.60 (s, 3H). **¹³C NMR** (101 MHz, CDCl_3) δ 157.8, 153.4, 146.5, 134.4, 127.1, 126.7, 126.5, 122.6, 64.2, 20.1. **HRMS** (ESI): m/z (M + H⁺) calcd for $\text{C}_{10}\text{H}_{11}\text{N}_2\text{O}_2$, 191.0820, found: 191.0815. **mp** 88–89 °C.

3-methoxy-2-methyl-7-phenylquinazolin-4(3*H*)-one (15)




White solid (48 mg, 91%), R_f = 0.6 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl_3) δ 8.22 (d, J = 8.3 Hz, 1H), 7.77 (s, 1H), 7.60 (d, J = 7.7 Hz, 3H), 7.44 – 7.39 (m, 2H), 7.37 – 7.32 (m, 1H), 4.07 (s, 3H), 2.59 (s, 3H). **¹³C NMR** (101 MHz, CDCl_3) δ 157.5, 153.7, 147.0, 146.7, 139.3, 129.0, 128.4, 127.3, 127.0, 125.4, 124.9, 121.2, 64.1, 20.0. **HRMS** (ESI): m/z (M + H⁺) calcd for $\text{C}_{16}\text{H}_{15}\text{N}_2\text{O}_2$, 267.1128, found: 267.1125. **mp** 107–108 °C.

3-methoxy-2,7-dimethylquinazolin-4(3*H*)-one (16)




Yellow solid (30 mg, 74%), R_f = 0.6 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl_3) δ 8.03 (d, J = 8.2 Hz, 1H), 7.31 (s, 1H), 7.23 – 7.05 (m, 1H), 4.03 (s, 3H), 2.53 (s, 3H), 2.39 (s, 3H). **¹³C NMR** (101 MHz, CDCl_3) δ 157.6, 153.3, 146.4, 145.2, 127.9, 126.7, 126.3, 120.0, 64.0, 21.8, 19.9. **HRMS** (ESI): m/z (M + H⁺) calcd for $\text{C}_{11}\text{H}_{13}\text{O}_2\text{N}_2$, 205.0972, found: 205.0972. **mp** 132–133 °C.

7-chloro-3-methoxy-2-methylquinazolin-4(3*H*)-one (17)



Yellow solid (38 mg, 85%), R_f = 0.6 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl_3) δ 8.16 (d, J = 8.6 Hz, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.38 (dd, J = 8.6, 1.9 Hz, 1H), 4.10 (s, 3H), 2.62 (s, 3H). **¹³C NMR** (101 MHz, CDCl_3) δ 157.3, 154.9, 147.4, 140.7, 128.2, 127.2, 126.8, 121.1, 64.3, 20.1. **HRMS** (ESI): m/z (M + H⁺) calcd for $\text{C}_{10}\text{H}_{10}\text{ClN}_2\text{O}_2$, 225.0425, found: 225.0428. **mp** 168–170 °C.


3-methoxy-2-methyl-7-nitroquinazolin-4(3*H*)-one (18)



Yellow solid (46 mg, 98%), R_f = 0.5 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl_3) δ 8.41 (d, J = 2.0 Hz, 1H), 8.38 (d, J = 8.8 Hz, 1H),


8.17 (dd, J = 8.8, 1.7 Hz, 1H), 4.13 (s, 3H), 2.66 (s, 3H). **^{13}C NMR** (101 MHz, CDCl_3) δ 156.7, 156.1, 151.6, 146.9, 128.6, 126.7, 122.8, 120.2, 64.4, 20.2. **HRMS (ESI)**: m/z (M + H $^+$) calcd for $\text{C}_{10}\text{H}_{10}\text{N}_3\text{O}_4$, 236.0666, found: 236.0664. **mp** 172–174 °C.

3-methoxy-2-methyl-7-(trifluoromethyl) quinazolin-4(3*H*)-one (19)




Yellow solid (49 mg, 94%), R_f = 0.4 (EtOAc/Petroleum ether = 1:1). **^1H NMR** (400 MHz, CDCl_3) δ 8.37 (d, J = 8.4 Hz, 1H), 7.93 (s, 1H), 7.65 (d, J = 8.4 Hz, 1H), 4.13 (s, 3H), 2.67 (s, 3H). **^{13}C NMR** (101 MHz, CDCl_3) δ 157.1, 155.2, 146.4, 136.2 (q, J = 33.0 Hz, -CF₃), 128.0, 125.0, 124.8 (q, J = 4.0 Hz), 122.6 (q, J = 3.4 Hz), 122.1, 64.4, 20.1. **HRMS (ESI)**: m/z (M + H $^+$) calcd for $\text{C}_{11}\text{H}_{10}\text{F}_3\text{N}_2\text{O}_2$, 259.0696, found: 259.0689. **mp** 102–103 °C.

3-methoxy-2,5-dimethylquinazolin-4(3*H*)-one (20)




White solid (27 mg, 65%), R_f = 0.6 (EtOAc/Petroleum ether = 1:1). **^1H NMR** (400 MHz, CDCl_3) δ 7.52 – 7.747 (m, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.12 (d, J = 7.3 Hz, 1H), 4.04 (s, 3H), 2.82 (s, 3H), 2.55 (s, 3H). **^{13}C NMR** (101 MHz, CDCl_3) δ 158.3, 153.0, 147.9, 141.2, 133.4, 129.0, 125.2, 120.9, 63.9, 22.7, 19.9. **HRMS (ESI)**: m/z (M + H $^+$) calcd for $\text{C}_{11}\text{H}_{13}\text{N}_2\text{O}_2$, 205.0972, found: 205.0971. **mp** 111–112 °C.

5-bromo-3-methoxy-2-methylquinazolin-4(3*H*)-one (21)




Yellow solid (48 mg, 90%), R_f = 0.4 (EtOAc/Petroleum ether = 1:1). **^1H NMR** (400 MHz, CDCl_3) δ 7.65 (dd, J = 7.7, 1.1 Hz, 1H), 7.54 (dd, J = 8.2, 1.0 Hz, 1H), 7.49 – 7.42 (m, 1H), 4.08 (s, 3H), 2.58 (s, 3H). **^{13}C NMR** (101 MHz, CDCl_3) δ 165.4, 156.1, 154.1, 148.7, 134.1, 133.1, 127.2, 121.2, 64.1, 20.1. **HRMS (ESI)**: m/z (M + H $^+$) calcd for $\text{C}_{10}\text{H}_{10}\text{BrN}_2\text{O}_2$, 268.9933, found: 268.9920. **mp** 140–141 °C.

3-methoxy-2,5,7-trimethylquinazolin-4(3*H*)-one (22)



White solid (40 mg, 91%), R_f = 0.6 (EtOAc/Petroleum ether = 1:1). **^1H NMR** (400 MHz, CDCl_3) δ 7.18 (s, 1H), 6.95 (s, 1H), 4.03 (s, 3H), 2.77 (s, 3H), 2.53 (s, 3H), 2.35 (s, 3H). **^{13}C NMR** (101 MHz, CDCl_3) δ 158.2, 153.0, 148.0, 144.3, 140.9, 130.5, 125.0, 118.4, 63.9, 22.6, 21.6, 19.9. **HRMS (ESI)**: m/z (M + H $^+$) calcd for $\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}_2$, 219.1128, found: 219.1128. **mp** 172–174 °C.


3-methoxy-2,7-dimethylquinazolin-4(3*H*)-one (23)



White solid (60 mg, 99%), R_f = 0.6 (EtOAc/Petroleum ether = 1:1). **^1H NMR** (400 MHz, CDCl_3) δ 8.30 (s, 1H), 7.96 (d, J = 1.5 Hz, 1H), 4.11 (s, 3H), 2.64 (d,


$J = 0.7$ Hz, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 156.5, 155.1, 145.4, 133.0, 132.3, 129.6, 127.5, 122.6, 64.4, 20.2. **HRMS** (ESI): m/z (M + H⁺) calcd for C₁₀H₉BrCIN₂O₂, 302.9530, found: 302.9533. **mp** 208–210 °C.

2-methoxy-3-methylbenzo[f]quinazolin-1(2*H*)-one (24)




White solid (48 mg, 99%), R_f = 0.2 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl₃) δ 9.78 (d, J = 8.6 Hz, 1H), 8.03 – 7.93 (m, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.67 (ddd, J = 8.5, 7.1, 1.3 Hz, 1H), 7.62 – 7.45 (m, 2H), 4.11 (s, 3H), 2.61 (s, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 157.9, 153.9, 148.3, 135.6, 131.3, 130.8, 128.7, 128.2, 126.6(X2), 125.6, 115.6, 64.0, 19.9. **HRMS** (ESI): m/z (M + H⁺) calcd for C₁₄H₁₃N₂O₂, 241.0972, found: 241.0970. **mp** 115–116 °C.

2-(*tert*-butyl)-8-methoxy-7-methyloxazolo[5,4-f] quinazolin-9(8*H*)-one (25)




White solid (44 mg, 77%), R_f = 0.3 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl₃) δ 8.00 (d, J = 8.7 Hz, 1H), 7.57 (d, J = 8.7 Hz, 1H), 4.15 (s, 3H), 2.65 (s, 3H), 1.55 (s, 9H). **¹³C NMR** (101 MHz, CDCl₃) δ 175.6, 154.8, 152.9, 147.5, 144.6, 139.8, 125.8, 123.6, 109.2, 64.4, 34.6, 28.7, 20.1. **HRMS** (ESI): m/z (M + H⁺) calcd for C₁₅H₁₈N₃O₃, 288.1352, found: 288.1343. **mp** 128–129 °C.

2-heptyl-3-methoxy-6-methylquinazolin-4(3*H*)-one (26)




White solid (52 mg, 90%), R_f = 0.7 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl₃) δ 8.05 (s, 1H), 7.59 – 7.52 (m, 2H), 4.10 (s, 3H), 2.86 (t, J = 7.7 Hz, 2H), 2.47 (s, 3H), 1.89 – 1.77 (m, 2H), 1.49 – 1.40 (m, 2H), 1.39 – 1.26 (m, 6H), 0.88 (t, J = 6.8 Hz, 3H). **¹³C NMR** (101 MHz, CDCl₃) δ 162.3, 158.1, 155.8, 136.8, 135.9, 127.1, 126.1, 122.3, 64.5, 32.8, 31.8, 29.5, 29.1, 27.0, 22.8, 21.4, 14.2. **HRMS** (ESI): m/z (M + H⁺) calcd for C₁₇H₂₅N₂O₂, 289.1918, found: 289.1911. **mp** 61–62 °C.

2-isopentyl-3-methoxy-6-methylquinazolin-4(3*H*)-one (27)




White solid (47 mg, 91%), R_f = 0.6 (EtOAc/Petroleum ether = 1:1). **¹H NMR** (400 MHz, CDCl₃) δ 7.96 (d, J = 0.8 Hz, 1H), 7.52 – 7.42 (m, 2H), 4.05 (s, 3H), 2.79 (dd, J = 10.1, 5.6 Hz, 2H), 2.40 (s, 3H), 1.71 – 1.61 (m, 3H), 0.97 – 0.90 (m, 6H). **¹³C NMR** (101 MHz, CDCl₃) δ 157.9, 155.6, 144.4, 136.5, 135.7, 127.0, 125.9, 122.1, 64.2, 35.6, 30.8, 28.0, 22.4, 21.2. **HRMS** (ESI): m/z (M + H⁺) calcd for C₁₅H₂₁N₂O₂, 261.1598, found: 261.1597. **mp** 46–47 °C.

2-(3-(benzyloxy)propyl)-3-methoxyquinazolin-4(3*H*)-one (28)




Yellow oil (61 mg, 94%), R_f = 0.6 (EtOAc/Petroleum ether = 1:1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.26 (dd, J = 8.0, 1.2 Hz, 1H), 7.75 – 7.71 (m, 1H), 7.67 – 7.63 (m, 1H), 7.47 – 7.42 (m, 1H), 7.33 – 7.30 (m, 4H), 7.28 (dd, J = 6.2, 2.4 Hz, 1H), 4.52 (s, 2H), 4.10 (s, 3H), 3.65 (t, J = 6.0 Hz, 2H), 3.04 – 3.00 (m, 2H), 2.22 – 2.17 (m, 2H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 158.1, 155.9, 146.6, 138.5, 134.4, 128.5, 127.7 (X2), 127.4, 126.7, 126.5, 122.6, 73.0, 69.3, 64.4, 29.4, 26.5. HRMS (ESI): m/z (M + H⁺) calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_3$, 325.1547, found: 325.1561.

2-isopropyl-3-methoxy-6-methylquinazolin-4(3*H*)-one (29)




Colourless oil (26 mg, 56%), R_f = 0.8 (EtOAc/Petroleum ether = 1:1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.04 (s, 1H), 7.58 (d, J = 8.3 Hz, 1H), 7.53 (dd, J = 8.3, 1.6 Hz, 1H), 4.10 (s, 3H), 3.33 (m, 1H), 2.47 (s, 3H), 1.38 (s, 3H), 1.36 (s, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 159.5, 158.3, 144.6, 136.6, 135.8, 127.4, 126.0, 122.2, 64.6, 30.4, 21.4, 20.8. HRMS (ESI): m/z (M + H⁺) calcd for $\text{C}_{13}\text{H}_{17}\text{N}_2\text{O}_2$, 233.1285, found: 233.1280.

3-methoxy-2,6-dimethylquinazolin-4(3*H*)-one (32)




White solid (43 mg, 81%), R_f = 0.7 (EtOAc/Petroleum ether = 1:1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.13 (s, 1H), 7.89 (dd, J = 7.9, 1.6 Hz, 2H), 7.69 (d, J = 8.3 Hz, 1H), 7.60 (dd, J = 8.3, 2.0 Hz, 1H), 7.55 – 7.49 (m, 3H), 3.76 (s, 3H), 2.52 (s, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 158.2, 152.5, 144.7, 137.5, 136.2, 132.2, 130.8, 129.5, 128.5, 127.9, 126.3, 122.5, 64.2, 21.5. HRMS (ESI): m/z (M + H⁺) calcd for $\text{C}_{16}\text{H}_{15}\text{N}_2\text{O}_2$, 267.1128, found: 267.1128. **mp** 111–112 °C.

2-(3-bromophenyl)-3-methoxy-6-methylquinazolin-4(3*H*)-one (33)




White solid (36 mg, 52%), R_f = 0.6 (EtOAc/Petroleum ether = 1:1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.11 (s, 1H), 8.07 – 8.04 (m, 1H), 7.89 – 7.76 (m, 1H), 7.66 (d, J = 8.2 Hz, 2H), 7.59 (dd, J = 8.4, 1.8 Hz, 1H), 7.40 – 7.34 (m, 1H), 3.78 (s, 3H), 2.51 (s, 3H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 157.9, 150.8, 144.5, 137.9, 136.2, 134.0, 133.9, 132.5, 129.9, 128.2, 128.0, 126.3, 122.5, 122.4, 64.3, 21.5. HRMS (ESI): m/z (M + H⁺) calcd for $\text{C}_{16}\text{H}_{14}\text{BrN}_2\text{O}_2$, 345.0233, found: 345.0228. **mp** 118–119 °C.


3-methoxy-2-(3-methoxyphenyl)-6-methylquinazolin-4(3*H*)-one (34)


 White solid (40 mg, 68%), R_f = 0.6 (EtOAc/Petroleum ether = 1:1). **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 8.11 (s, 1H), 7.67 (d, J = 8.3 Hz, 1H), 7.58 (dd, J = 8.3, 1.8 Hz, 1H), 7.46 (d, J = 7.7 Hz, 1H), 7.40 (dd, J = 9.8, 6.0 Hz, 2H), 7.14 – 6.99 (m, 1H), 3.86 (s, 3H), 3.77 (s, 3H), 2.50 (s, 3H). **$^{13}\text{C NMR}$** (101 MHz, CDCl_3) δ 159.4, 158.1, 152.3, 144.6, 137.5, 136.1, 133.4, 129.5, 127.9, 126.2, 122.5, 121.8, 116.9, 114.7, 64.2, 55.6, 21.4. **HRMS** (ESI): m/z (M + H $^+$) calcd for $\text{C}_{17}\text{H}_{17}\text{N}_2\text{O}_3$, 297.1234, found: 297.1229. **mp** 113–114 °C.


2-methylquinolin-4(3H)-one (35)


 To a suspension of **14** (38 mg, 0.2 mmol) in THF (5 mL) and MeOH (5 mL) was added Pd/C (10%, 320 mg) and stirred at room temperature under a H_2 atmosphere. After the starting material was consumed completely, the reaction mixture was filtered and washed with MeOH. The filtrate was concentrated and purified by silica gel chromatography to afford **35** (30 mg, 94%) as white solid. R_f = 0.3 (EtOAc/Petroleum ether = 3:1). **$^1\text{H NMR}$** (400 MHz, DMSO-d_6) δ 12.18 (br s, 1H), 8.07 (dd, J = 7.9, 1.3 Hz, 1H), 7.79 – 7.73 (m, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.47 – 7.1 (m, 1H), 2.34 (s, 3H). **$^{13}\text{C NMR}$** (101 MHz, DMSO-d_6) δ 161.7, 154.2, 149.0, 134.2, 126.6, 125.8, 125.6, 120.6, 21.4. **HRMS** (ESI): m/z (M + H $^+$) calcd for $\text{C}_9\text{H}_9\text{N}_2\text{O}_1$, 161.0713, found: 161.0709. **mp** 198–200 °C.

(Z)-2-((2-oxoindolin-3-ylidene)methyl)quinazolin-4(3H)-one (36)



 To a suspension of **35** (160 mg, 1 mmol) in AcOH (5 mL) was added isatin (147 mg, 1 mmol) and stirred at 120°C until the starting material was consumed completely, the reaction mixture was filtered and washed with MeOH to obtain compound **36**² as orange solid (260 mg, 90%), R_f = 0.2 (EtOAc/Petroleum ether = 1:1). **$^1\text{H NMR}$** (400 MHz, DMSO-d_6) δ 14.40 (br s, 1H), 11.49 (br s, 1H), 8.18 (d, J = 7.8 Hz, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.92 – 7.86 (m, 1H), 7.79 (d, J = 7.7 Hz, 1H), 7.67 – 7.56 (m, 2H), 7.40 – 7.34 (m, 1H), 7.13 – 7.07 (m, 1H), 6.95 – 6.90 (m, 1H). **$^{13}\text{C NMR}$** (101 MHz, DMSO-d_6) δ 168.8, 160.8, 150.4, 148.9, 141.6, 134.7, 134.3, 131.7, 130.0, 128.0 (X2), 126.0, 123.3, 122.6, 122.0, 121.5, 110.6. **HRMS** (ESI): m/z (M + H $^+$) calcd for $\text{C}_{17}\text{H}_{12}\text{O}_2\text{N}_3$, 290.0931, found: 290.0924. **mp** >220 °C.

3-(2,3-dihydroxypropyl)-2-methylquinazolin-4(3H)-one (37)


 To a magnetically stirred mixture of **35** (160 mg, 1 mmol) and glycidol (74 mg, 1 mmol) was added $\text{Zn}(\text{ClO}_4)_2 \cdot 6\text{H}_2\text{O}$ (7.5 mg, 2 mol%) under


neat condition at room temperature and the stirring was continued for 30 minutes. The crude reaction mixture was purified by flash column chromatography to obtain **37**³ as white solid (222 mg, 95%). **1H NMR** (400 MHz, DMSO-*d*6) δ 8.09 (dd, *J* = 7.9, 0.9 Hz, 1H), 7.79 – 7.75 (m, 1H), 7.57 (d, *J* = 8.1 Hz, 1H), 7.48 – 7.44 (m, 1H), 5.09 – 5.04 (m, 1H), 4.79 – 4.74 (m, 1H), 4.33 – 4.24 (m, 1H), 3.85 (dd, *J* = 14.8, 5.5 Hz, 2H), 3.44 (d, *J* = 4.3 Hz, 2H), 2.65 (s, 3H). **13C NMR** (101 MHz, DMSO-*d*6) δ 161.4, 156.2, 147.2, 134.1, 126.4, 126.0, 126.0, 120.1, 68.8, 64.2, 47.7, 23.6. **HRMS** (ESI): m/z (M + H⁺) calcd for C₁₂H₁₅N₂O₃, 235.1085, found: 235.1077. **mp** 142–144 °C.

2,6-dimethylquinazolin-4(3*H*)-one (**39**)




To a suspension of **3ea** (40.8 mg, 0.2 mmol) in THF (5 mL) and MeOH (5 mL) was added Pd/C (10%, 320 mg) and stirred at room temperature under H₂ atmosphere overnight. When the starting material was consumed completely, the reaction mixture was filtered and washed with MeOH. The filtrate was concentrated and purified by silica gel chromatography to afford **39** (32 mg, 92%) as white solid. R_f = 0.3 (EtOAc/Petroleum ether = 3:1). **1H NMR** (400 MHz, DMSO-*d*6) δ 12.09 (s, 1H), 7.86 (s, 1H), 7.58 (dd, *J* = 8.3, 1.8 Hz, 1H), 7.46 (d, *J* = 8.3 Hz, 1H), 2.41 (s, 3H), 2.32 (s, 3H). **13C NMR** (101 MHz, DMSO-*d*6) δ 161.6, 153.3, 146.9, 135.5, 135.3, 126.4, 125.0, 120.4, 21.3, 20.7. **HRMS** (ESI): m/z (M + H⁺) calcd for C₁₀H₁₁N₂O₁, 175.0871, found: 175.0866. **mp** 205–206 °C.

6-(bromomethyl)-2-methylquinazolin-4(3*H*)-one (**40**)



A mixture of **39** (52.2 mg, 0.3 mmol), *N*-bromosuccinimide (59 mg, 0.33 mmol) and benzoyl peroxide (9 mg, 0.036 mmol) in 20 mL chloroform was stirred at 60°C under infrared heat lamp, and the white precipitate was formed after 2h. The reaction mixture was cooled by ice bath and then filtered. The filter cake was washed with chloroform three times (3 × 15 mL) and dried, compound **40** was obtained as white solid (48 mg, 64%).⁴ R_f = 0.2 (EtOAc/Petroleum ether = 2:1). **1H NMR** (400 MHz, DMSO-*d*6) δ 12.30 (br s, 1H), 8.15 (d, *J* = 1.8 Hz, 1H), 7.82 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.61 – 7.50 (m, 1H), 4.86 (s, 2H), 2.36 (s, 3H). **13C NMR** (101 MHz, DMSO-*d*6) δ 161.3, 155.1, 148.3, 135.8, 135.4, 126.8, 126.3, 120.5, 33.8, 21.4. **HRMS** (ESI): m/z (M + H⁺) calcd for C₁₀H₁₀BrN₂O, 252.9982, found: 252.9971. **mp** >220 °C.


2-(3-hydroxypropyl)quinazolin-4(3*H*)-one (**42**)



To a suspension of **28** (64 mg, 0.2 mmol) in THF (5 mL) and MeOH (5 mL) was added Pd/C (10%, 320 mg) and stirred at room temperature under S20


H_2 atmosphere overnight. When the starting material was consumed completely, the reaction mixture was filtered and washed with MeOH. The filtrate was concentrated and purified by silica gel chromatography. White solid (37 mg, 91%), $\text{R}_f = 0.4$ (DCM/MeOH = 25:1). $^1\text{H NMR}$ (400 MHz, DMSO-*d*6) δ 8.07 (dd, *J* = 7.9, 1.1 Hz, 1H), 7.78 – 7.73 (m, 1H), 7.58 (d, *J* = 8.2 Hz, 1H), 7.47 – 7.41 (m, 1H), 3.47 (t, *J* = 6.4 Hz, 2H), 2.67 – 2.61 (m, 2H), 1.92 – 1.84 (m, 2H). $^{13}\text{C NMR}$ (101 MHz, DMSO-*d*6) δ 161.9, 157.6, 148.9, 134.3, 126.7, 125.9, 125.7, 120.8, 60.1, 31.3, 29.8. HRMS (ESI): m/z (M + H $^+$) calcd for $\text{C}_{11}\text{H}_{13}\text{N}_2\text{O}_2$, 205.0972, found: 205.0973.

2,3-dihydropyrrolo[2,1-*b*]quinazolin-9(1*H*)-one (43)



To a solution of **42** (204 mg, 1.0 mmol) and triphenylphosphine (340 mg, 1.3 mmol) in THF (3 mL), a solution of DEAD (190 mg, 1.1 mmol) in THF (2 mL) was added in a dropwise fashion, and the reaction mixture was stirred for 3h. The reaction mixture was concentrated, and the residue was purified by silica gel. White solid (167 mg, 90%), $\text{R}_f = 0.2$ (EtOAc/Petroleum ether = 1:1). $^1\text{H NMR}$ (400 MHz, DMSO-*d*6) δ 8.11 (d, *J* = 7.9 Hz, 1H), 7.80–7.74 (m, 1H), 7.60 (d, *J* = 8.1 Hz, 1H), 7.50 – 7.44 (m, 1H), 4.06 (t, *J* = 7.2 Hz, 2H), 3.08 (t, *J* = 7.9 Hz, 2H), 2.16 (dd, *J* = 14.9, 7.6 Hz, 2H). $^{13}\text{C NMR}$ (101 MHz, DMSO-*d*6) δ 160.4, 160.0, 149.0, 134.1, 126.6, 125.9, 125.7, 120.1, 46.3, 31.8, 18.9. HRMS (ESI): m/z (M + H $^+$) calcd for $\text{C}_{11}\text{H}_{11}\text{N}_2\text{O}$, 187.0866, found: 187.0867. **mp** 106–107 °C.


(8*R*,9*S*,13*S*,14*S*)-*N*-methoxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6*H*-cyclopenta[a]phenanthrene-3-carboxamide (46)



Ethyl (8*R*,9*S*,13*S*,14*S*)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6*H*-cyclopenta[a]phenanthrene-3-carboxylate (326 mg, 1 mmol)⁵ was added to a biphasic mixture of LiOH (72 mg, 3 mmol) in a 2:1 mixture of THF (9 mL) and H₂O (4.5 mL). The resulting solution was stirred at room temperature overnight. The solvent was evaporated under the reduced pressure and EtOAc was used to extract the product from the aqueous layer. The combined organic layer was washed with water (3×50 mL), dried over Na₂SO₄, filtered and concentrated to afford the corresponding carboxylic acid (200 mg, 67%), which was used to produce the title compound according to method B as white solid (203 mg, 62%), $\text{R}_f = 0.5$ (EtOAc/Petroleum ether = 1:1). $^1\text{H NMR}$ (400 MHz, CDCl₃) δ 8.67 (br s, 1H), 7.55 – 7.45 (m, 2H), 7.35 – 7.33 (m, 1H), 3.89 (s, 3H), 2.99 – 2.89 (m, 2H), 2.52 (dd, *J* = 18.7, 8.5 Hz, 1H), 2.44 (dd, *J* = 9.9, 2.3 Hz,

1H), 2.36 – 2.30 (m, 1H), 2.17 (dd, J = 18.5, 9.3 Hz, 1H), 2.09 – 2.02 (m, 2H), 1.98 (dd, J = 9.6, 1.9 Hz, 1H), 1.60 – 1.46 (m, 6H), 0.92 (s, 3H). **^{13}C NMR** (101 MHz, CDCl_3) δ 220.7, 144.4, 137.4, 131.1, 128.0, 125.9, 125.4, 124.2, 64.8, 50.6, 48.0, 44.7, 38.0, 36.0, 31.7, 29.4, 26.4, 25.7, 21.7, 14.0. **MS** (m/z) [M + H] $^+$: 328.19.

(3a*S*,3b*R*,11b*S*,13a*S*)-8-methoxy-9,13a-dimethyl-3,3a,3b,4,5,8,11b,12,13,13a-decahydro-1*H*-cyclopenta[5,6]naphtho[2,1-*g*]quinazoline-1,7(2*H*)-dione (47)



White solid (67 mg, 92%), R_f = 0.5 (EtOAc/Petroleum ether = 1:1). **^1H NMR** (400 MHz, CDCl_3) δ 7.97 (s, 1H), 7.57 (s, 1H), 4.10 (s, 3H), 3.11 – 2.97 (m, 2H), 2.63 (s, 3H), 2.56 – 2.49 (m, 1H), 2.43 – 2.36 (m, 1H), 2.17 (d, J = 10.1 Hz, 1H), 2.10 – 1.96 (m, 4H), 1.64 – 1.50 (m, 6H), 0.91 (s, 3H). **^{13}C NMR** (101 MHz, CDCl_3) δ 220.4, 157.4, 153.6, 148.5, 143.3, 136.8, 126.2, 122.6, 119.9, 64.5, 50.8, 48.0, 44.9, 37.6, 35.9, 31.6, 29.1, 26.3, 25.6, 21.8, 19.5, 13.9. **HRMS** (ESI): m/z (M + H $^+$) calcd for $\text{C}_{22}\text{H}_{27}\text{N}_2\text{O}_3$, 367.2027, found: 367.2016. **mp** 168–170 °C.

Reference:

1. Y. Park, K. T. Park, J. G. Kim, S. Chang, *J. Am. Chem. Soc.*, 2015, **137**, 4534
2. Uehata K, Kimura N, Hasegawa K, et al. *J. Nat. Prod.*, 2013, **76**, 2034.
3. Kumar D, Jadhavar P S, Nautiyal M, et al. *RSC Adv.*, 2015, **5**, 30819
4. Zhan X, Xu Y, Qi Q, et al. *Chem. Biodivers.*, 2018, **15**, e1700513.
5. Liang A, Han S, Wang L, et al. *Adv. Synth. Catal.*, 2015, **357**, 3104.

